Сравнительная оценка клинической эффективности терапии тоцилизумабом и ритуксимабом у больных ревматоидным артритом
https://doi.org/10.14412/1995-4484-2012-1112
Аннотация
Об авторах
Anastasia Sergeyevna AvdeyevaЕлена Николаевна Александрова
Е. Ю. Панасюк
Г. В. Лукина
Евгений Львович Насонов
Список литературы
1. <div><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008; 290-331.</p><p>Samuels J., Ng Y.S., Coupillaud C. et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-67.</p><p>Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите. Науч-практич ревматол 2009;1(Прил.):3-22.</p><p>Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.</p><p>Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.</p><p>Smolen J.S., Aletaha D., Bijsma J.WJ. et al. For the T2T Exspert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.</p><p>Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2009;2:21-9.</p><p>Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.</p><p>Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер aрх 2010;5:64-71.</p><p>Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лабораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч-практич ревматол 2011;3:14-9.</p><p>Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.</p><p>Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практич ревматол 2011;4:11 -6.</p><p>Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.</p><p>Burmester G., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.</p><p>Emery P., Fleishmann R., Filipowicz-Sosnowska A. et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthr Rheum 2006;54:1390-400</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793-806.</p><p>Emery P., Deodhar A., Rigby W.F. et al. Efficacy and safety of different doses and retreatment of Rituximab: a randomized, placebo-controlled trial in patients who are biologically naive with active rheumatoid arthritis and anadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX inadequate responders (SERENA)). Ann Rheum Dis 2010;69:1629-35</p><p>Rubbert-Roth A., Tak P.P., Zebrini C. et al. Efficacy and safety of various repeat treatment dosing regimes in Rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). Rheumatology 2010;49:1683-93.</p><p>McGonagle D., Tan A., Madden J. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology 2008;47:865-7.</p><p>Assous N., Gossec L., Dieude P. Rituximab therapy in rheumatoid arthritis in daily practice. Rheumatology 2008;35:2.</p><p>Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.</p><p>Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7:796-806.</p><p>Rintelen B., Sautner J., Haindl P. et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;38:336-41.</p><p>Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015-22.</p><p>Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24.</p><p>Fransen J., Creemers C., van Reil P.L.C.M. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS 28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.</p><p>Felson D., Smolen J., Wells G. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Arthr Rheum 2011;63:573-86.</p><p>Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80.</p><p>Kremer J., Fleischmann R., Brzezicki J. et al. Tocilzumab inhibits structural joint damage, improved physical function, and increase DAS 28 remission rates in RA patients who respond inadequately to methotrexate: the LITHE study. Ann Rheum Dis 2009;68(Suppl.3):122 (OP-0157).</p><p>Leffers H., Ostergaard M., Glintborg B. Rheumatoid arthritis patients treated in routine care - efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70 (Suppl.3):463.</p><p>Yoshida K., Kishimoto M., Tokuda Y. Tocilizumab vs TNF inhibitors: difference in the quality of remission. Ann Rheum Dis 2011;70(Suppl.3):470.</p><p>Tak P., Rigby W., Rubbert-Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.</p><p>Sellam J., Abbedd K., Rouanet S. et al. Pre-therapeutic descrease frequency of memory B cell is predictive of response to a first course of Rituximab in rheumatoid arthritis patients with inade-quate respose or intolerance to anti-TNF: data from the SMART trial. Ann Rheum Dis 2010;69(Suppl.3):490 [SAT0014].</p><p>Maini P., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817-29.</p><p>Emery P., Keystone E., Tony H.-P. IL-6 receptor inhibition with tocilizumab improves arthritis refractory to anti-TNF biologics: results treatment outcomes in patients with rheumatoid from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23.</p><p>Sibilia J., Graninger W., Ostor A. et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011;70 (Suppl.3):466.</p><p>Nakazaki S., Murayama T., Kato S. The validity of 28-joint disease activity scoring using ESR in rheumatoid arthritis with tocilizumab. Ann Rheum Dis 2011;70(Suppl.3):618.</p><p>Smolen J., Kavanaugh A., Tony H.P. et al. Rituximab significantly improves the clinical and simplified disease activity index (CDAI, SDAI) scores in patients with rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors (REFLEX). Ann Rheum Dis 2007;66(Suppl.II):439.</p><p>Smolen J., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis. Arthr Rheum 2011;63:43-52.</p><p>Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90.</p></div><br />
Рецензия
Для цитирования:
Avdeyeva A.S., Александрова Е.Н., Панасюк Е.Ю., Лукина Г.В., Насонов Е.Л. Сравнительная оценка клинической эффективности терапии тоцилизумабом и ритуксимабом у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(4):49-56. https://doi.org/10.14412/1995-4484-2012-1112
For citation:
Avdeyeva A.S., Aleksandrova E.N., Panasyuk E.Yu., Lukina G.V., Nasonov E.L. Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2012;50(4):49-56. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1112